# E2022 Patch Formulation Multiple Dose Study

> **NCT01450839** · PHASE1 · COMPLETED · sponsor: **Eisai Co., Ltd.** · enrollment: 16 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** E2022
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01450839
- **Lead sponsor:** Eisai Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2011-11
- **Final completion:** 2012-02
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2012-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01450839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01450839, "E2022 Patch Formulation Multiple Dose Study". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01450839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*